{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:08Z","timestamp":1760298068160},"reference-count":141,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.blre.2009.03.001","type":"journal-article","created":{"date-parts":[[2009,4,11]],"date-time":"2009-04-11T08:11:45Z","timestamp":1239437505000},"page":"205-216","source":"Crossref","is-referenced-by-count":19,"title":["Molecular biology of mantle cell lymphoma: From profiling studies to new therapeutic strategies"],"prefix":"10.1016","volume":"23","author":[{"given":"Ant\u00f2nia","family":"Obrador-Hevia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Fern\u00e1ndez de","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priam","family":"Villalonga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","article-title":"A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors","volume":"38","author":"Andersen","year":"2002","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2009.03.001_bib3","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/annonc\/9.suppl_5.S25","article-title":"World Health Organization Classification of lymphomas: a work in progress","volume":"9","author":"Jaffe","year":"1998","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/modpathol.3880035","article-title":"The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997","volume":"13","author":"Harris","year":"2000","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.blre.2009.03.001_bib6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/01.pas.0000208899.15859.cb","article-title":"Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study","volume":"30","author":"Salar","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib7","first-page":"377","article-title":"Messenger RNA levels of five genes located at chromosome 11q13 in B-cell tumors with chromosome translocation t(11;14)(q13;q32)","volume":"54","author":"Akiyama","year":"1994","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2009.03.001_bib8","first-page":"S8","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues A progress report","volume":"111","author":"Jaffe","year":"1999","journal-title":"Am J Clin Pathol"},{"issue":"13","key":"10.1016\/j.blre.2009.03.001_bib9","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2009.03.001_bib10","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1080\/10428190310001623775","article-title":"Gene expression profiling of diffuse large B-cell lymphoma","volume":"44","author":"Rosenwald","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib11","first-page":"2253","article-title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma","volume":"95","author":"Yatabe","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib12","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/j.1460-2075.1994.tb06488.x","article-title":"Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene","volume":"13","author":"Bodrug","year":"1994","journal-title":"Embo J"},{"issue":"15","key":"10.1016\/j.blre.2009.03.001_bib13","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","article-title":"Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice","volume":"13","author":"Lovec","year":"1994","journal-title":"Embo J"},{"issue":"6046","key":"10.1016\/j.blre.2009.03.001_bib14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.onc.1209147","article-title":"Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma","volume":"25","author":"Gladden","year":"2006","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib16","first-page":"253","article-title":"Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl","volume":"4","author":"Langdon","year":"1989","journal-title":"Oncogene Res"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","article-title":"Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/j.1460-2075.1989.tb03435.x","article-title":"N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc","volume":"8","author":"Rosenbaum","year":"1989","journal-title":"Embo J"},{"issue":"6189","key":"10.1016\/j.blre.2009.03.001_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/labinvest.3780061","article-title":"Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin\u2019s lymphomas xenotransplanted in severe combined immunodeficiency mouse models","volume":"80","author":"Bryant","year":"2000","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0165-4608(02)00823-3","article-title":"Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model","volume":"143","author":"M\u2019Kacher","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib22","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1158\/1078-0432.CCR-07-4409","article-title":"A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma","volume":"14","author":"Wang","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2009.03.001_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.leu.2404177","article-title":"Murine model for mantle cell lymphoma","volume":"20","author":"Smith","year":"2006","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2009.03.001_bib24","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1182\/blood-2006-08-038497","article-title":"Development of a murine model for blastoid variant mantle-cell lymphoma","volume":"109","author":"Ford","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1365-2141.2002.03260.x","article-title":"Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization","volume":"116","author":"Allen","year":"2002","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2009.03.001_bib26","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Bea","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.0.CO;2-M","article-title":"T(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia","volume":"27","author":"Bentz","year":"2000","journal-title":"Gene Chromosome Cancer"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1080\/10428190410001683796","article-title":"High incidence of unbalanced chromosomal changes in mantle cell lymphoma detected by comparative genomic hybridization","volume":"45","author":"Jarosova","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2003-12-4175","article-title":"Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions","volume":"104","author":"Kohlhammer","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/(SICI)1098-2264(199804)21:4<298::AID-GCC3>3.0.CO;2-U","article-title":"Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma","volume":"21","author":"Monni","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.blre.2009.03.001_bib31","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature","volume":"25","author":"Salaverria","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/modpathol.3800237","article-title":"Mantle cell lymphomas with clonal immunoglobulin V(H)3\u201321 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes","volume":"18","author":"Thelander","year":"2005","journal-title":"Mod Pathol"},{"issue":"17","key":"10.1016\/j.blre.2009.03.001_bib33","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/hmg\/ddh195","article-title":"Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes","volume":"13","author":"de Leeuw","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib34","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.leukres.2006.10.022","article-title":"Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma","volume":"31","author":"Flordal Thelander","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","article-title":"Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas","volume":"109","author":"Mestre-Escorihuela","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2009.03.001_bib36","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","article-title":"Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome","volume":"105","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib37","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2004-07-2730","article-title":"Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization","volume":"105","author":"Schraders","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2009.03.001_bib38","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","article-title":"Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM","volume":"24","author":"Tagawa","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2009.03.001_bib39","doi-asserted-by":"crossref","unstructured":"Vater I, Wagner F, Kreuz M, Berger H, Martin-Subero JI, Pott C, et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol 2008.","DOI":"10.1111\/j.1365-2141.2008.07443.x"},{"key":"10.1016\/j.blre.2009.03.001_bib40","doi-asserted-by":"crossref","unstructured":"Bea S, Salaverria I, Armengol L, Pinyol M, Fernandez V, Hartmann EM, et al. Uniparental disomies, homozygous deletions, amplifications and target genes in mantle cell lymphoma revealed by integrative high-resolution whole genome profiling. Blood 2008.","DOI":"10.1182\/blood-2008-07-170183"},{"issue":"5","key":"10.1016\/j.blre.2009.03.001_bib41","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.leu.2404173","article-title":"Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma","volume":"20","author":"Nielaender","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1471-2407-8-106","article-title":"Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis","volume":"8","author":"Blenk","year":"2008","journal-title":"BMC Cancer"},{"issue":"6769","key":"10.1016\/j.blre.2009.03.001_bib43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.blre.2009.03.001_bib45","first-page":"4398","article-title":"Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells","volume":"62","author":"Ek","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib46","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V98.3.787","article-title":"Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray","volume":"98","author":"Hofmann","year":"2001","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2009.03.001_bib47","first-page":"8226","article-title":"The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival","volume":"63","author":"Martinez","year":"2003","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2005.05883.x","article-title":"Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma","volume":"132","author":"Rinaldi","year":"2006","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2009.03.001_bib49","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood.V99.12.4554","article-title":"Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes","volume":"99","author":"Korz","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1365-2141.2003.04121.x","article-title":"Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma","volume":"120","author":"Nagy","year":"2003","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2009.03.001_bib51","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/sj.leu.2401533","article-title":"Quantitative analysis detects ubiquitous expression of apoptotic regulators in B cell non-Hodgkin\u2019s lymphomas","volume":"13","author":"Xerri","year":"1999","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/path.1768","article-title":"Expression of the NF-kappaB targets BCL2 and BIRC5\/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively","volume":"206","author":"Tracey","year":"2005","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0092-8674(93)90136-E","article-title":"Functional interactions of the retinoblastoma protein with mammalian D-type cyclins","volume":"73","author":"Ewen","year":"1993","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.blre.2009.03.001_bib54","first-page":"4608","article-title":"Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma","volume":"57","author":"Dreyling","year":"1997","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.blre.2009.03.001_bib55","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/sj.leu.2401090","article-title":"Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb","volume":"12","author":"Gronbaek","year":"1998","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2009.03.001_bib56","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V91.8.2977.2977_2977_2984","article-title":"P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin\u2019s lymphomas","volume":"91","author":"Pinyol","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib57","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2009.03.001_bib58","first-page":"2409","article-title":"BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas","volume":"61","author":"Bea","year":"2001","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2009.03.001_bib59","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-04-1526","article-title":"CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a\/ARF locus","volume":"65","author":"Hernandez","year":"2005","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.blre.2009.03.001_bib60","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1182\/blood-2006-11-057208","article-title":"Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis","volume":"109","author":"Pinyol","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2009.03.001_bib62","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Fernandez","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/1042819031000151112","article-title":"Altered apoptosis pathways in mantle cell lymphoma","volume":"45","author":"Rummel","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib64","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2004-10-3999","article-title":"Proteomic analysis of mantle-cell lymphoma by protein microarray","volume":"105","author":"Ghobrial","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.blre.2009.03.001_bib66","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib67","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways","volume":"130","author":"Rizzatti","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib68","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00108-007-1803-3","article-title":"Therapy of mantle cell lymphoma","volume":"48","author":"Dreyling","year":"2007","journal-title":"Internist (Berl)"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2005.10.980","article-title":"Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2009.03.001_bib70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib71","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib72","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2009.03.001_bib73","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first remission: the prognostic value of B2m and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.blre.2009.03.001_bib74","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2009.03.001_bib75","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib76","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med"},{"issue":"Pt 16","key":"10.1016\/j.blre.2009.03.001_bib77","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1242\/jcs.114.16.2903","article-title":"PKB\/Akt: a key mediator of cell proliferation, survival and insulin responses?","volume":"114","author":"Lawlor","year":"2001","journal-title":"J Cell Sci"},{"issue":"20","key":"10.1016\/j.blre.2009.03.001_bib78","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1073\/pnas.211430998","article-title":"AKT plays a central role in tumorigenesis","volume":"98","author":"Testa","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.blre.2009.03.001_bib79","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2009.03.001_bib80","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1073\/pnas.91.26.12574","article-title":"RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12\/rapamycin complex","volume":"91","author":"Chiu","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"10.1016\/j.blre.2009.03.001_bib81","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib82","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.V91.2.561","article-title":"The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines","volume":"91","author":"Kawamata","year":"1998","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2009.03.001_bib83","doi-asserted-by":"crossref","first-page":"14424","DOI":"10.1074\/jbc.273.23.14424","article-title":"Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability","volume":"273","author":"Hashemolhosseini","year":"1998","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.blre.2009.03.001_bib84","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","article-title":"Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma","volume":"169","author":"Peponi","year":"2006","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.blre.2009.03.001_bib85","first-page":"1433","article-title":"Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells","volume":"90","author":"Hipp","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib86","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","article-title":"Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma","volume":"36","author":"Yazbeck","year":"2008","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib87","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.blre.2009.03.001_bib88","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.blre.2009.03.001_bib89","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib90","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0092-8674(00)81318-5","article-title":"NF-kappa B: ten years after","volume":"87","author":"Baeuerle","year":"1996","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib92","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-kappaB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.blre.2009.03.001_bib93","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/sj.cdd.4401888","article-title":"NF-kappaB and the regulation of hematopoiesis","volume":"13","author":"Bottero","year":"2006","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib94","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4049\/jimmunol.178.3.1923","article-title":"Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level","volume":"178","author":"Roue","year":"2007","journal-title":"J Immunol"},{"issue":"26","key":"10.1016\/j.blre.2009.03.001_bib95","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1200\/JCO.2005.05.014","article-title":"Targeting histones and proteasomes: new strategies for the treatment of lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib96","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V95.2.619","article-title":"Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma","volume":"95","author":"Chiarle","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib97","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib98","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib99","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib100","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.blre.2009.03.001_bib101","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib102","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.blre.2009.03.001_bib103","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib104","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib105","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1046\/j.1365-2141.2002.03586.x","article-title":"Chromatin modification, leukaemia and implications for therapy","volume":"118","author":"Jones","year":"2002","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib106","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","article-title":"Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma","volume":"76","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib107","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","article-title":"Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines","volume":"33","author":"Sakajiri","year":"2005","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib108","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib109","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O\u2019Connor","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma","volume":"80","author":"Heider","year":"2008","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib111","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt0998-833","article-title":"Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection","volume":"16","author":"Morimoto","year":"1998","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib112","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2141.2006.06247.x","article-title":"The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9","volume":"135","author":"Georgakis","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2009.03.001_bib113","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0092-8674(93)90636-5","article-title":"Mammalian G1 cyclins","volume":"73","author":"Sherr","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib114","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(94)90540-1","article-title":"G1 phase progression: cycling on cue","volume":"79","author":"Sherr","year":"1994","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.blre.2009.03.001_bib115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","article-title":"Preclinical and clinical development of cyclin-dependent kinase modulators","volume":"92","author":"Senderowicz","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib116","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib117","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/annonc\/mdi217","article-title":"In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas","volume":"16","author":"Lacrima","year":"2005","journal-title":"Ann Oncol"},{"issue":"38","key":"10.1016\/j.blre.2009.03.001_bib118","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1038\/sj.onc.1210350","article-title":"Evaluation of novel cell cycle inhibitors in mantle cell lymphoma","volume":"26","author":"Park","year":"2007","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.blre.2009.03.001_bib119","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2004.05239.x","article-title":"Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab","volume":"127","author":"Ramanarayanan","year":"2004","journal-title":"Br J Haematol"},{"issue":"30","key":"10.1016\/j.blre.2009.03.001_bib120","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia","volume":"23","author":"O\u2019Brien","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2009.03.001_bib121","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1535-7163.MCT-07-0302","article-title":"Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels","volume":"7","author":"Tucker","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.blre.2009.03.001_bib122","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","article-title":"Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma","volume":"111","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib123","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","article-title":"The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies","volume":"112","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2009.03.001_bib124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10428190701713655","article-title":"The role of TRAIL death receptors in the treatment of hematological malignancies","volume":"49","author":"Henson","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.blre.2009.03.001_bib125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/01.cad.0000217432.71741.da","article-title":"Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma","volume":"17","author":"Eucker","year":"2006","journal-title":"Anticancer Drugs"},{"issue":"9","key":"10.1016\/j.blre.2009.03.001_bib126","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2403058","article-title":"Thalidomide therapy induces response in relapsed mantle cell lymphoma","volume":"17","author":"Damaj","year":"2003","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2009.03.001_bib127","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2009.03.001_bib128","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1073\/pnas.94.22.12070","article-title":"Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism","volume":"94","author":"Langenfeld","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/0008-5472.587.65.2","article-title":"Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma","volume":"65","author":"Guidoboni","year":"2005","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.blre.2009.03.001_bib130","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0959-8049(02)00166-1","article-title":"Farnesyl transferase inhibitors as anticancer agents","volume":"38","author":"Haluska","year":"2002","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.blre.2009.03.001_bib131","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1182\/blood-2005-06-2584","article-title":"The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT","volume":"106","author":"David","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2009.03.001_bib132","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-007-0543-3","article-title":"Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma","volume":"61","author":"Rolland","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.blre.2009.03.001_bib133","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/ni823","article-title":"PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling","volume":"3","author":"Su","year":"2002","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.blre.2009.03.001_bib134","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2559.2007.02666.x","article-title":"Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies","volume":"50","author":"Decouvelaere","year":"2007","journal-title":"Histopathology"},{"issue":"16","key":"10.1016\/j.blre.2009.03.001_bib135","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib136","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib137","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1158\/0008-5472.CAN-06-1962","article-title":"Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments","volume":"67","author":"Lepelletier","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2009.03.001_bib138","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.leukres.2004.06.009","article-title":"Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma","volume":"29","author":"Ek","year":"2005","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.blre.2009.03.001_bib139","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1074\/mcp.M600077-MCP200","article-title":"From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies","volume":"5","author":"Ek","year":"2006","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"10.1016\/j.blre.2009.03.001_bib140","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2007-02-068791","article-title":"Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference","volume":"111","author":"Ortega-Paino","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2009.03.001_bib141","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/ijc.21579","article-title":"Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4\u20131BB-L implicated in cell survival","volume":"118","author":"Ek","year":"2006","journal-title":"Int J Cancer"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X09000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X09000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T20:22:50Z","timestamp":1684959770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X09000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":141,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0268960X09000204"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2009.03.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}